Table 1:
Characteristics of the 299-person Cohort at Enrollment
| Age, years | 60 (52–66) | |
| Education, years | 14 (12 – 16) | |
| Sex, male | 169 (56.3%) | |
| Body Mass Index, kg/m2 | 29 (26 – 34) | |
| Etiology* | ||
| Other | 25% | |
| Hepatocellular Carcinoma | 22 (7.3%) | |
| Child class A | 209 (70%) | |
| Varices | 229 (76%) | |
| Ascites | 122 (41%) | |
| Ascites requiring paracentesis (at any point) | 30 (10%) | |
| Platelet count < 80,000 | 111 (37%) | |
| Any current alcohol use | 92 (31%) | |
| Current alcohol abuse | 22 (7.3%) | |
| Charlson Comorbidity Index | 4 (1 – 4) | |
| Laboratory Values | ||
| MELD-Na | 9 (7 – 13) | |
| Bilirubin (mg/dL) | 1 (0.7 – 1.6) | |
| Creatinine (mg/dL) | 0.9 (0.7 – 1.04) | |
| INR | 1.1 (1 – 1.2) | |
| Sodium (meq/L) | 140 (138 – 141) | |
| Albumin (mg/dL) | 4 (3.6–4.3) | |
| Markers of Frailty | ||
| Incompletely independent in ADLs | 27 (9%) | |
| Chair stands | 10 (7– 13) | |
| Hand grip, kilograms | 31 (22 – 39) | |
| Self-reported falls in past 6 months | 65 (22%) | |
| Medication Reconciliation (chronic current use) | ||
| Diuretics | 120 (40%) | |
| Nonselective Beta-blockers | 180 (60%) | |
| Benzodiazepine | 55 (18%) | |
| Opioid | 66 (22%) | |
| Antidepressant | 54 (18%) | |
| Inhibitory Control Test (ICT) Performance | ||
| Lures | 12 (7 –22) | |
| Targets | 94.3 (84 – 98) | |
| Weighted lures | 14.5 (8.2 – 37.8) | |
| Cannot complete ICT | 38 (13%) | |
ADL = activities of daily living, INR = international normalized ratio, MELD-Na = model for endstage liver disease – sodium, NAFLD = nonalcoholic fatty liver disease